Literature DB >> 35844223

Mechanistic Models of Protein Aggregation Across Length-Scales and Time-Scales: From the Test Tube to Neurodegenerative Disease.

Georg Meisl1, Tuomas P J Knowles1,2, David Klenerman1,3.   

Abstract

Through advances in the past decades, the central role of aberrant protein aggregation has been established in many neurodegenerative diseases. Crucially, however, the molecular mechanisms that underlie aggregate proliferation in the brains of affected individuals are still only poorly understood. Under controlled in vitro conditions, significant progress has been made in elucidating the molecular mechanisms that take place during the assembly of purified protein molecules, through advances in both experimental methods and the theories used to analyse the resulting data. The determination of the aggregation mechanism for a variety of proteins revealed the importance of intermediate oligomeric species and of the interactions with promotors and inhibitors. Such mechanistic insights, if they can be achieved in a disease-relevant system, provide invaluable information to guide the design of potential cures to these devastating disorders. However, as experimental systems approach the situation present in real disease, their complexity increases substantially. Timescales increase from hours an aggregation reaction takes in vitro, to decades over which the process takes place in disease, and length-scales increase to the dimension of a human brain. Thus, molecular level mechanistic studies, like those that successfully determined mechanisms in vitro, have only been applied in a handful of living systems to date. If their application can be extended to further systems, including patient data, they promise powerful new insights. Here we present a review of the existing strategies to gain mechanistic insights into the molecular steps driving protein aggregation and discuss the obstacles and potential paths to achieving their application in disease. First, we review the experimental approaches and analysis techniques that are used to establish the aggregation mechanisms in vitro and the insights that have been gained from them. We then discuss how these approaches must be modified and adapted to be applicable in vivo and review the existing works that have successfully applied mechanistic analysis of protein aggregation in living systems. Finally, we present a broad mechanistic classification of in vivo systems and discuss what will be required to further our understanding of aggregate formation in living systems.
Copyright © 2022 Meisl, Knowles and Klenerman.

Entities:  

Keywords:  amyloid; chemical kinetics; in vivo models; mechanistic models; neurodegenerative disease; protein aggregation

Year:  2022        PMID: 35844223      PMCID: PMC9281552          DOI: 10.3389/fnins.2022.909861

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   5.152


  89 in total

1.  Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein.

Authors:  Ryuichiro Atarashi; Roger A Moore; Valerie L Sim; Andrew G Hughson; David W Dorward; Henry A Onwubiko; Suzette A Priola; Byron Caughey
Journal:  Nat Methods       Date:  2007-07-22       Impact factor: 28.547

2.  Quantification of the concentration of Aβ42 propagons during the lag phase by an amyloid chain reaction assay.

Authors:  Paolo Arosio; Risto Cukalevski; Birgitta Frohm; Tuomas P J Knowles; Sara Linse
Journal:  J Am Chem Soc       Date:  2013-12-20       Impact factor: 15.419

Review 3.  Amyloid biomarkers in Alzheimer's disease.

Authors:  Kaj Blennow; Niklas Mattsson; Michael Schöll; Oskar Hansson; Henrik Zetterberg
Journal:  Trends Pharmacol Sci       Date:  2015-04-01       Impact factor: 14.819

4.  The role of clearance mechanisms in the kinetics of pathological protein aggregation involved in neurodegenerative diseases.

Authors:  T B Thompson; G Meisl; T P J Knowles; A Goriely
Journal:  J Chem Phys       Date:  2021-03-28       Impact factor: 3.488

Review 5.  Secondary nucleation in amyloid formation.

Authors:  Mattias Törnquist; Thomas C T Michaels; Kalyani Sanagavarapu; Xiaoting Yang; Georg Meisl; Samuel I A Cohen; Tuomas P J Knowles; Sara Linse
Journal:  Chem Commun (Camb)       Date:  2018-08-02       Impact factor: 6.222

Review 6.  Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis.

Authors:  Adriano Aguzzi
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

7.  Proteopathic tau seeding predicts tauopathy in vivo.

Authors:  Brandon B Holmes; Jennifer L Furman; Thomas E Mahan; Tritia R Yamasaki; Hilda Mirbaha; William C Eades; Larisa Belaygorod; Nigel J Cairns; David M Holtzman; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-26       Impact factor: 11.205

8.  Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides.

Authors:  Georg Meisl; Xiaoting Yang; Erik Hellstrand; Birgitta Frohm; Julius B Kirkegaard; Samuel I A Cohen; Christopher M Dobson; Sara Linse; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-17       Impact factor: 11.205

9.  Super-resolution imaging reveals α-synuclein seeded aggregation in SH-SY5Y cells.

Authors:  Jason C Sang; Eric Hidari; Georg Meisl; Rohan T Ranasinghe; Maria Grazia Spillantini; David Klenerman
Journal:  Commun Biol       Date:  2021-05-21

10.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.

Authors:  Samuel I A Cohen; Sara Linse; Leila M Luheshi; Erik Hellstrand; Duncan A White; Luke Rajah; Daniel E Otzen; Michele Vendruscolo; Christopher M Dobson; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.